We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.4%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$111M
AUM Growth
-$3.2M
Cap. Flow
+$4.3M
Cap. Flow %
3.86%
Top 10 Hldgs %
57.45%
Holding
59
New
25
Increased
8
Reduced
9
Closed
16

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.1M
2
TMO icon
Thermo Fisher Scientific
TMO
+$7.38M
3
BRKR icon
Bruker
BRKR
+$6.46M
4
AVTR icon
Avantor
AVTR
+$4.83M
5
CNMD icon
CONMED
CNMD
+$4.82M

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$7.86M
2
CI icon
Cigna
CI
+$5.63M
3
A icon
Agilent Technologies
A
+$5.5M
4
BDX icon
Becton Dickinson
BDX
+$3.53M
5
IQV icon
IQVIA
IQV
+$3.31M

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Real Estate 4.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$11.6B
$15.9M 14.27%
179,568
+135,966
+312% +$12.1M
TMO icon
2
Thermo Fisher Scientific
TMO
$213B
$7.01M 6.3%
+13,849
New +$7.38M
BRKR icon
3
Bruker
BRKR
$9.57B
$6.93M 6.23%
111,276
+96,030
+630% +$6.46M
AZN icon
4
AstraZeneca
AZN
$263B
$6.53M 5.87%
48,222
+17,818
+59% +$2.43M
ELV icon
5
Elevance Health
ELV
$81.5B
$5.88M 5.28%
13,501
+7,865
+140% +$3.57M
AVTR icon
6
Avantor
AVTR
$9.32B
$4.78M 4.3%
+226,877
New +$4.83M
MRK icon
7
Merck
MRK
$322B
$4.57M 4.1%
44,384
-4,948
-10% -$533K
ARGX icon
8
argenx
ARGX
$53.4B
$4.48M 4.02%
9,108
+6,543
+255% +$3.2M
CNMD icon
9
CONMED
CNMD
$1.39B
$4.23M 3.8%
+41,984
New +$4.82M
COO icon
10
Cooper Companies
COO
$14.1B
$3.67M 3.29%
+46,132
New +$4.25M
HUM icon
11
Humana
HUM
$43.7B
$3.2M 2.88%
+6,584
New +$3.09M
TXG icon
12
10x Genomics
TXG
$6B
$2.93M 2.63%
+71,044
New +$3.7M
SBRA icon
13
Sabra Healthcare REIT
SBRA
$5.34B
$2.84M 2.55%
+203,792
New +$2.61M
OHI icon
14
Omega Healthcare
OHI
$15.1B
$2.66M 2.38%
+80,070
New +$2.56M
BSX icon
15
Boston Scientific
BSX
$69.5B
$2.53M 2.27%
47,893
-13,098
-21% -$687K
KIDS icon
16
OrthoPediatrics
KIDS
$519M
$2.25M 2.02%
70,364
+59,623
+555% +$2.3M
COR icon
17
Cencora
COR
$60.6B
$2.09M 1.88%
+11,606
New +$2.14M
SYK icon
18
Stryker
SYK
$125B
$2.06M 1.85%
+7,547
New +$2.16M
INSM icon
19
Insmed
INSM
$21.4B
$2.01M 1.8%
79,471
– –
ZBH icon
20
Zimmer Biomet
ZBH
$18.2B
$1.96M 1.76%
+17,479
New +$2.22M
QDEL icon
21
QuidelOrtho
QDEL
$1.14B
$1.95M 1.75%
+26,747
New +$2.14M
DXCM icon
22
DexCom
DXCM
$31.5B
$1.93M 1.73%
+20,694
New +$2.33M
THC icon
23
Tenet Healthcare
THC
$20.5B
$1.79M 1.61%
27,151
-30,885
-53% -$2.31M
ABT icon
24
Abbott
ABT
$183B
$1.75M 1.57%
+18,040
New +$1.89M
CI icon
25
Cigna
CI
$73.7B
$1.74M 1.56%
6,083
-19,733
-76% -$5.63M
1
2 3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Endurant Capital Management held 59 positions worth $111M, down 2.8% from $115M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Endurant Capital Management deployed $4.3M of net new capital in Q3 2023, opening 25 new positions and adding to 8 existing holdings. Its largest new stake was Thermo Fisher Scientific: 13,849 shares worth $7.01M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 66% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Cigna, an estimated $5.63M trimmed.

  • Endurant Capital Management's largest Q3 2023 buy was Thermo Fisher Scientific: 13,849 shares worth $7.01M.
  • Endurant Capital Management added most to BioMarin Pharmaceuticals in Q3 2023, an estimated $12.1M increase.
  • Endurant Capital Management's biggest Q3 2023 reduction was Cigna, cutting an estimated $5.63M.
  • Endurant Capital Management fully exited Labcorp in Q3 2023, selling an estimated $7.86M.
  • Endurant Capital Management's ten largest holdings make up 57% of its $111M portfolio in Q3 2023.
  • Endurant Capital Management opened 25 new positions and closed 16 in Q3 2023.
  • Endurant Capital Management's portfolio value fell 2.8% quarter-over-quarter to $111M.

Based on Endurant Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.